*Applications will be reviewed on a rolling- basis, and this posting will remain open until filled.
A research opportunity is currently available in the Office of Blood Research and Review (OBRR) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
This project will focus on evaluating the safety and efficacy of genetically modified live attenuated Leishmania parasite vaccines in pre-clinical experimental models. The selected participant will receive mentoring and training necessary to achieve the goals of the project. This project includes collaboration with investigators within or external to FDA. The participant will learn several analytical techniques including Flow Cytometry, RT-PCR, and bioinformatic analysis. The participant will be investigating the role of early biomarkers in protective immunity induced by immunization with live attenuated Leishmania parasites in appropriate animal models. The participant is expected to help collect, analyze and present the data to senior investigators on a regular basis.
Anticipated Appointment Start Date: February 2022; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for five months, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment- related benefits.